



Rcadia - Company Profile

The COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography

Rcadia Medical Imaging AuntMinnie’s 2009 “Best New Radiology Vendor” winner, develops and markets its proprietary automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company’s first FDA-cleared product, The COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography (cCTA) to enable the practical application of cCTA in detecting coronary artery disease. The COR Analyzer System improves the utility of coronary CTA in the emergency department (ED), to triage chest pain patients and optimizes workflow in cardiology and radiology departments.


Rcadias Goal

Rcadia’s systems are designed to provide advanced technology solutions to major clinical and economic challenges in the diagnosis and management of CAD and other blood vessel disorders. The company’s first product, The COR Analyzer System, performs fully automated analysis of cCTA studies in real time in patients with suspected CAD. The COR Analyzer System is the first system approved in the U.S. for use in coronary artery disease.

Need for Improved Blood Vessel Analysis Tools

Coronary Artery Disease (CAD) and stroke, the consequences of atherosclerosis, are leading causes of mortality in the U.S., accounting nearly 25 percent of deaths. CAD alone, Rcadia’s initial focus, affects some 16 million people in the U.S., causes 1.2 million heart attacks, and over 450,000 deaths. The direct costs of CAD are estimated at over \$87 billion.

Timely and accurate evaluation of suspected CAD patients is among the keys to improving patient care, reducing costs, and improving efficiency in delivering care. For example, for the six million patients who enter ED in the U.S. each year with chest pain, the central challenge is to identify rapidly those who need immediate treatment and rule out non-cardiac patients.



THE COR ANALYZER® SYSTEM AUTOMATICALLY DETECTS CORONARY ARTERY NARROWING

However, nearly 85 percent of these cases are false alarms. Because current diagnostic techniques are often equivocal, nearly two million, primarily low risk, patients are admitted to hospitals for further testing at an annual cost of \$10-\$13 billion, where acute coronary syndrome is subsequently ruled out. Additionally, 3-5 percent of patients are discharged from the ED due to missed diagnoses. Such missed diagnoses account for approximately 20 percent of ED-related malpractice cases.



Rcadia Medical Imaging
“Best New Radiology Vendor”
– AuntMinnie.com, 2009

COR Analyzer® System

cCTA, is performed utilizing 64 slice and higher CTs with contrast media to produce three-dimensional images of coronary arteries. This non-invasive procedure has generated significant clinical interest in recent years for coronary blood vessel analysis, particularly as a means to rule out patients without significant disease. Published studies have suggested that cCTA may significantly reduce the time and cost of Acute Coronary Syndrome (ACS) triage in the ED in low risk patients. The American Medical Association recently classified cCTA as Category I in its CPT coding system, indicating the procedure is widely used in clinical practice and its efficacy has been documented in published literature. In 2009, AuntMinnie.com, a leading on-line radiology forum, designated cCTA as the “hottest clinical procedure.”

However, there are several challenges associated with the use of cCTA. Special expertise is required to successfully interpret the results. This requirement, along with time needed to analyze cCTA studies, can create turnaround time bottlenecks that hinder the timeliness of delivering appropriate patient care. The COR Analyzer addresses these issues by providing a rapid, clinical decision making support tool that improves workflow in the ED as well as in cardiology and radiology department settings.

Management

Hillel Bachrach, Chairman
20/20 HealthCare Partners

Shai Levanon, President and CEO

Roman Goldenberg, Ph.D., VP R&D

Bob Lenkinsky, Ph.D. (consultant)
Harvard Medical School

Major Investors

20/20 HealthCare Partners

BioVentures Investors

www.rcadia.com

The Rcadia system works with images acquired on 64-slice or higher CTA machine. It operates seamlessly in the background, processing patient image data sets from cCTA and generating comprehensive results and corresponding reports within minutes. The system's software determines the presence of significant lesions (more than 50 percent stenosis) in coronary arteries and provides the needed visualization tools, allowing the clinician to validate the findings and see the precise location of detected lesions. In 2009, AuntMinnie recognized Rcadia and the COR Analyzer with its annual award for best new radiology vendor.



The COR Analyzer System received 510(k) approval for marketing in the U.S. based on analysis of hundreds of cCTA procedures involving all four 64 slice CTA manufacturers. The company is collaborating with clinicians at a number of leading academic centers and hospitals in the U.S.A. and abroad to document the system's benefits. In addition, the company is exploring additional applications in blood vessel analysis.

Key COR Analyzer Features and Benefits

Features

- High Negative Predictive Value
- Rapid, fully automated analysis
- Detects/Displays Severe Lesions
- Integration with CT scans

Benefits

- Improved triage in ED to reduce
 - time to treatment
 - hospital admissions/costs
 - staffing needs
- Enhanced cardiology, radiology dept. workflow by
 - prioritizing patients
 - accelerating analysis
 - improving sensitivity with 'second' reader